secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001645113-24-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure Q1 net revenue up 13% to $138.5M; METIS trial meets endpoint, FDA decision on lung cancer PMA expected H2 2024
--------------------------------------------------------------------------------

- Net revenue $138.5M (+13% YoY); net loss $38.8M ($0.36 loss per share); adjusted EBITDA -$4.6M.
- Active patients 3,845; prescriptions received 1,643 (+10% YoY).
- METIS Phase 3 met primary endpoint (brain metastases from NSCLC); will be presented at ASCO.
- LUNAR PMA for Optune Lua in NSCLC: Day 100 FDA meeting productive, decision expected H2 2024.
- Entered $400M senior secured credit facility with Pharmakon Advisors (non-dilutive).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000014/0001645113-24-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000014/nvcr-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer